Innate Pharma (IPHA) Operating Expenses (2019 - 2025)

Innate Pharma (IPHA) has reported Operating Expenses for 7 consecutive years, with -$71.7 million the latest figure, recorded in Q4 2025.

• Quarterly Operating Expenses rose 12.11% year-over-year to -$71.7 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was -$231.7 million (up 9.59% YoY) and the FY2025 annual result came in at $71.7 million, down 12.11% from the prior year.
• Operating Expenses eased to -$71.7 million in Q4 2025 per IPHA's latest filing, from -$34.5 million in the prior quarter.
• Over the last five years, Operating Expenses for IPHA reached as high as -$34.5 million in Q2 2025 and fell as low as -$84.6 million in Q4 2023.
• A 5-year average of -$61.8 million and a median of -$59.2 million in 2021 frame the typical range for Operating Expenses.
• Annual changes were most pronounced in 2023 — Operating Expenses slipped 9.44% — and 2025, when it grew 21.65%.
• Year by year, Operating Expenses stood at -$82.5 million in 2021, then fell by 2.17% to -$84.3 million in 2022, then retreated by 0.28% to -$84.6 million in 2023, then rose by 3.52% to -$81.6 million in 2024, then advanced by 12.11% to -$71.7 million in 2025.
• According to Business Quant data, Operating Expenses over the past three periods registered -$71.7 million, -$34.5 million, and -$81.6 million for Q4 2025, Q2 2025, and Q4 2024 respectively.